Quest Diagnostics Inc (NYSE:DGX) SVP Jon R. Cohen sold 83,669 shares of Quest Diagnostics stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $104.20, for a total value of $8,718,309.80. Following the transaction, the senior vice president now owns 115,426 shares in the company, valued at $12,027,389.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Quest Diagnostics Inc (DGX) traded down $1.39 during trading hours on Monday, hitting $105.60. The company had a trading volume of 1,020,000 shares, compared to its average volume of 1,190,000. The company has a current ratio of 1.24, a quick ratio of 1.15 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $14,320.00, a P/E ratio of 22.33, a P/E/G ratio of 1.92 and a beta of 0.68. Quest Diagnostics Inc has a twelve month low of $90.10 and a twelve month high of $112.96.
Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, February 1st. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. Quest Diagnostics’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.31 earnings per share. research analysts anticipate that Quest Diagnostics Inc will post 6.59 EPS for the current year.
Large investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Quest Diagnostics in the third quarter valued at about $446,000. AXA increased its position in shares of Quest Diagnostics by 38.7% in the third quarter. AXA now owns 80,875 shares of the medical research company’s stock valued at $7,573,000 after acquiring an additional 22,575 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Quest Diagnostics by 4.7% in the third quarter. Schwab Charles Investment Management Inc. now owns 510,114 shares of the medical research company’s stock valued at $47,768,000 after acquiring an additional 22,798 shares during the last quarter. National Pension Service grew its holdings in Quest Diagnostics by 9.5% during the fourth quarter. National Pension Service now owns 155,469 shares of the medical research company’s stock worth $15,312,000 after purchasing an additional 13,460 shares during the period. Finally, Acropolis Investment Management LLC grew its holdings in Quest Diagnostics by 39.8% during the fourth quarter. Acropolis Investment Management LLC now owns 5,905 shares of the medical research company’s stock worth $582,000 after purchasing an additional 1,682 shares during the period. 88.65% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have weighed in on DGX shares. Goldman Sachs Group initiated coverage on Quest Diagnostics in a report on Monday, January 29th. They set a “buy” rating and a $117.00 target price on the stock. Mizuho set a $113.00 price target on Quest Diagnostics and gave the company a “buy” rating in a research note on Wednesday, January 24th. Canaccord Genuity reissued a “buy” rating and issued a $110.00 price target on shares of Quest Diagnostics in a research note on Tuesday, January 16th. Zacks Investment Research raised Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 price target on the stock in a research note on Tuesday, February 6th. Finally, Argus raised Quest Diagnostics from a “hold” rating to a “buy” rating and lifted their price target for the company from $104.14 to $116.00 in a research note on Wednesday, March 7th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $108.10.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/03/12/insider-selling-quest-diagnostics-inc-dgx-svp-sells-83669-shares-of-stock.html.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.